SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Eletriptan Hydrobromide Film Coated Tablets

Trade Name: RELPAX; RELERT; ELETRIPTAN-PFIZER
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product for the treatment of migraine headache

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Acute Oral Toxicity: Category 4
Serious Eye Damage/Eye Irritation: Category 1

Label Elements

Signal Word: Danger
Hazard Statements: H302 - Harmful if swallowed
H318 - Causes serious eye damage

Precautionary Statements: P264 - Wash hands thoroughly after handling
P270 - Do not eat, drink or smoke when using this product
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P301+ P312 - IF SWALLOWED: Call a POISON CENTRE or doctor/physician if you feel unwell
P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing
P310 - Immediately call a POISON CENTRE or doctor/physician
P330 - Rinse mouth
P501 - Dispose of contents/container in accordance with all local and national regulations



Other Hazards No data available
Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Eletriptan hydrobromide	177834-92-3	Not Listed	Acute Tox.4 (H302) Eye Dam. 1 (H318) Aquatic Acute 3 (H402) Aquatic Chronic 3 (H412)	23.42
Titanium dioxide	13463-67-7	236-675-5	Not Listed	*
Microcrystalline cellulose	9004-34-6	232-674-9	Not Listed	*
Magnesium stearate	557-04-0	209-150-3	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Croscarmellose sodium	74811-65-7	Not Listed	Not Listed	*
Triacetin	102-76-1	203-051-9	Not Listed	*
Hydroxypropyl methylcellulose	9004-65-3	Not Listed	Not Listed	*
Lactose NF, monohydrate	64044-51-5	Not Listed	Not Listed	*
FD&C yellow No.6 aluminum lake	15790-07-5	239-888-1	Not Listed	*

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. Minimize dust generation and accumulation. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Refer to Section 12 - Ecological Information, for information on potential effects on the environment. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Eletriptan hydrobromide

Pfizer OEL TWA-8 Hr:	0.1 mg/m³

Titanium dioxide

ACGIH Threshold Limit Value (TWA)	10 mg/m³
ACGIH OELs - Notice of Intended Changes	Listed
Australia TWA	10 mg/m³
Austria OEL - MAKs	5 mg/m³
Belgium OEL - TWA	10 mg/m³
Bulgaria OEL - TWA	10.0 mg/m³
Denmark OEL - TWA	6 mg/m³
Estonia OEL - TWA	5 mg/m³
France OEL - TWA	10 mg/m³
Greece OEL - TWA	10 mg/m³ 5 mg/m³
Ireland OEL - TWAs	10 mg/m³ 4 mg/m³
Latvia OEL - TWA	10 mg/m³
Lithuania OEL - TWA	5 mg/m³
OSHA - Final PELS - TWAs:	15 mg/m³
Poland OEL - TWA	10.0 mg/m³
Portugal OEL - TWA	10 mg/m³
Romania OEL - TWA	10 mg/m³
Russia OEL - TWA	10 mg/m³
Spain OEL - TWA	10 mg/m³
Sweden OEL - TWAs	5 mg/m³
Switzerland OEL -TWAs	3 mg/m³
Vietnam OEL - TWAs	6 mg/m³ 5 mg/m³

Microcrystalline cellulose

ACGIH Threshold Limit Value (TWA)	10 mg/m³
Australia TWA	10 mg/m³
Belgium OEL - TWA	10 mg/m³
Estonia OEL - TWA	10 mg/m³
France OEL - TWA	10 mg/m³
Ireland OEL - TWAs	10 mg/m³ 4 mg/m³
Latvia OEL - TWA	2 mg/m³
OSHA - Final PELS - TWAs:	15 mg/m³
Portugal OEL - TWA	10 mg/m³
Romania OEL - TWA	10 mg/m³
Russia OEL - TWA	6 mg/m³
Spain OEL - TWA	10 mg/m³
Switzerland OEL -TWAs	3 mg/m³
Vietnam OEL - TWAs	10 mg/m³ 5 mg/m³

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Magnesium stearate

ACGIH Threshold Limit Value (TWA)	10 mg/m^3
Lithuania OEL - TWA	5 mg/m^3
Sweden OEL - TWAs	5 mg/m^3

Exposure Controls

Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Wear impervious gloves to prevent skin contact.
Eyes:	Wear safety goggles as minimum protection.
Skin:	Wear impervious protective clothing to prevent skin contact.
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Tablet	**Color:**	Orange
Odor:	No data available.	**Odor Threshold:**	No data available.
Molecular Formula:	Mixture	**Molecular Weight:**	Mixture

Solvent Solubility:	No data available
Water Solubility:	No data available
pH:	No data available.
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Eletriptan hydrobromide
Measured Log P 3.45

Magnesium stearate
No data available

Croscarmellose sodium
No data available

Lactose NF, monohydrate
No data available

Microcrystalline cellulose
No data available

Hydroxypropyl methylcellulose
No data available

Triacetin
No data available

Titanium dioxide
No data available

FD&C yellow No.6 aluminum lake
No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s):	No data available
Vapor Pressure (kPa):	No data available

Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammablity:
- **Autoignition Temperature (Solid) (°C):** No data available
- **Flammability (Solids):** No data available
- **Flash Point (Liquid) (°C):** No data available
- **Upper Explosive Limits (Liquid) (% by Vol.):** No data available
- **Lower Explosive Limits (Liquid) (% by Vol.):** No data available

Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
- **Oxidizing Properties:** No data available
- **Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions.
- **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers
- **Hazardous Decomposition Products:** No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: There are no data for this formulation. The information included in this section describes the potential hazards of eletriptan in hydrobromide and/or hemisulfate salt forms. The remaining information describes the potential hazards of the individual ingredients.
Short Term: Active ingredient may be harmful if swallowed. May cause respiratory tract irritation. (based on components) .
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on liver, thyroid, heart.
Known Clinical Effects: Adverse effects most commonly reported in clinical use include weakness, sleepiness, nausea and dizziness

Acute Toxicity: (Species, Route, End Point, Dose)

Eletriptan hydrobromide
Rat Dermal LD50 2000mg/kg
Rat/Mouse Oral LD50 100-1000mg/kg (hemisulfate)
Rat/Mouse IV LDmin. 20mg/kg (hemisulfate)

Magnesium stearate
Rat Oral LD50 > 2000 mg/kg
Rat Inhalation LC50 > 2000 mg/m^3

Microcrystalline cellulose
Rat Oral LD50 > 5000 mg/kg
Rabbit Dermal LD50 > 2000 mg/kg

Hydroxypropyl methylcellulose
Rat Oral LD50 > 10,000 mg/kg

11. TOXICOLOGICAL INFORMATION

Triacetin
Rat Oral LD 50 3000 mg/kg
Mouse Oral LD 50 1100mg/kg

Titanium dioxide
Rat Oral LD50 > 7500 mg/kg
Rat Subcutaneous LD50 50 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Eletriptan hydrobromide
Eye Irritation Rabbit Very severe
Skin Irritation Rabbit Non-irritating
Antigenicity- Passive cutaneous anaphylaxis Guinea Pig Negative
Antigenicity- Active anaphylaxis Guinea Pig Negative

Microcrystalline cellulose
Skin Irritation Rabbit Non-irritating
Eye Irritation Rabbit Non-irritating

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Eletriptan hydrobromide
1 Month(s) Rat Oral5 mg/kg/day NOAEL Liver, Thyroid
6 Month(s) Rat Oral 15 mg/kg/day NOAEL Liver
6 Month(s) Dog Oral 1.25 mg/kg/day NOAEL Heart
12 Month(s) Dog Oral 0.75 mg/kg/day NOAEL Heart
24 Month(s) Mouse Oral 20 mg/kg/day NOAEL Liver, Thyroid

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Eletriptan hydrobromide
Reproductive & Fertility Rat Oral50 mg/kg/day NOAEL No effects at maximum dose
Embryo / Fetal Development Rat Oral 10 mg/kg/day NOAEL Maternal Toxicity, Fetotoxicity
Embryo / Fetal Development Rabbit Oral 10 mg/kg/day NOAEL Maternal Toxicity, Not Teratogenic
Peri-/Postnatal Development Rat Oral 15 mg/kg/day NOAEL Maternal Toxicity, Neonatal toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Eletriptan hydrobromide
Bacterial Mutagenicity (Ames) *Salmonella* , *E. coli* Negative
Mammalian Cell Mutagenicity Chinese Hamster Ovary (CHO) cells Negative
In Vitro Chromosome Aberration Human Lymphocytes Negative
In Vivo Micronucleus Mouse Bone Marrow Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Eletriptan hydrobromide

11. TOXICOLOGICAL INFORMATION

24 Month(s) Mouse Oral, in feed 400 mg/kg/day NOAEL Not carcinogenic
24 Month(s) Rat Oral 75 mg/kg/day NOAEL Not carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Titanium dioxide
IARC: Group 2B (Possibly Carcinogenic to Humans)

12. ECOLOGICAL INFORMATION

Environmental Overview: In the environment, the active ingredient in this formulation is expected to remain in water or migrate through the soil to groundwater Harmful effects to aquatic organisms could occur. Releases to the environment should be avoided.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Eletriptan hydrobromide
Daphnia magna (Water Flea) TAD OECD LC50 48 Hours 29 mg/L

Persistence and Degradability: No data available

Bio-accumulative Potential:
Partition Coefficient: (Method, pH, Endpoint, Value)
Eletriptan hydrobromide
Measured Log P 3.45

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Eletriptan hydrobromide

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

Croscarmellose sodium

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Triacetin

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	203-051-9

Titanium dioxide

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	carcinogen initial date 9/2/11 airborne, unbound particles of respirable size
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	236-675-5

Microcrystalline cellulose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex XVII - Restrictions on Certain Dangerous Substances:	Use restricted. See item 9[f]. powder
EU EINECS/ELINCS List	232-674-9

Hydroxypropyl methylcellulose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	Not Listed

15. REGULATORY INFORMATION

Lactose NF, monohydrate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	Not Listed

Magnesium stearate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3

FD&C yellow No.6 aluminum lake

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	239-888-1

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
Serious eye damage/eye irritation-Cat.1; H318 - Causes serious eye damage
Hazardous to the aquatic environment, acute toxicity-Cat.3; H402 - Harmful to aquatic life
Hazardous to the aquatic environment, chronic toxicity-Cat.3; H412 - Harmful to aquatic life with long lasting effects

Data Sources:	Safety data sheets for individual ingredients. Pfizer proprietary drug development information.
Reasons for Revision:	Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 16 - Other Information.
Revision date:	02-Jun-2016
Prepared by:	Product Stewardship Hazard Communication Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet